Emma Kang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emma Kang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Amanda Wietrzny
Versiti Blood Research Institute, Milwaukee, WI
1 shared publicationBrenda Ma
Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, Canada
1 shared publicationChristian J. Kastrup
Michael Smith Laboratories, University of British Columbia, Vancouver, BC, Canada
1 shared publication- Colton Strong
Department of Biochemistry and Molecular Biology University of British Columbia Vancouver British Columbia Canada
1 shared publication - Dana V. Devine
Department of Pathology and Laboratory Medicine University of British Columbia Vancouver British Columbia Canada
1 shared publication Deaglan Arnold
NanoVation Therapeutics, Vancouver, BC, Canada
1 shared publication
Latest Publications
- 21 November 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (21) , 2223-2236
Genetic engineering of transfusable platelets with mRNA-lipid nanoparticles is compatible with blood banking practices
Platelets contribute to a variety of physiological processes, including inflammation, sepsis, and cancer. However, because of their primary role in hemostasis, platelet transfusions are largely restricted to managing thrombocytopenia and bleeding. One way to expand the utility of platelet transfusions would be to genetically engineer donor platelets with new or enhanced functions. We have previously shown that lipid nanoparticles containing mRNA (mRNA-LNP) can be used to genetically modify authentic platelets in a nonclinical crystalloid solution. Currently, platelets collected for transfusion are stored in plasma or in plasma supplemented with platelet additive solution (PAS) at supraphysiological concentrations at room temperature, or at 4°C if intended for use in acute hemorrhage. Here, we describe a new plasma-optimized mRNA-LNP for transfecting platelets directly in plasma and plasma supplemented with PAS that is scalable to physiological and supraphysiological platelet concentrations. Transfecting platelets in clinical solutions with mRNA-LNP does not affect aspects of in vitro physiology, and transfected platelets are storable. The compatibility of this transfection system with current clinical practices could enable future mRNA-LNP–based platelet products and cell therapies.
- 21 November 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (21) , 2223-2236
Genetic engineering of transfusable platelets with mRNA-lipid nanoparticles is compatible with blood banking practices
Platelets contribute to a variety of physiological processes, including inflammation, sepsis, and cancer. However, because of their primary role in hemostasis, platelet transfusions are largely restricted to managing thrombocytopenia and bleeding. One way to expand the utility of platelet transfusions would be to genetically engineer donor platelets with new or enhanced functions. We have previously shown that lipid nanoparticles containing mRNA (mRNA-LNP) can be used to genetically modify authentic platelets in a nonclinical crystalloid solution. Currently, platelets collected for transfusion are stored in plasma or in plasma supplemented with platelet additive solution (PAS) at supraphysiological concentrations at room temperature, or at 4°C if intended for use in acute hemorrhage. Here, we describe a new plasma-optimized mRNA-LNP for transfecting platelets directly in plasma and plasma supplemented with PAS that is scalable to physiological and supraphysiological platelet concentrations. Transfecting platelets in clinical solutions with mRNA-LNP does not affect aspects of in vitro physiology, and transfected platelets are storable. The compatibility of this transfection system with current clinical practices could enable future mRNA-LNP–based platelet products and cell therapies.